SAN DIEGO, Sept. 9, 2016 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a molecular diagnostics company commercializing and
developing blood-based liquid biopsies to provide information to
physicians to improve the diagnosis and treatment of cancer,
announces a research collaboration with Shilpa Gupta, Ph.D., Assistant Professor in the
Hematology Oncology and Transplantation Division of the
University of Minnesota to observe the
utility of Biocept's patented Target Selector™ liquid biopsy
technology platform using circulating tumor cells (CTCs) to detect
the expression of PD-L1 and androgen receptor (AR) in patients
diagnosed with bladder and prostate cancers. The study will
be conducted at the University of
Minnesota Masonic Cancer Center. PD-L1 is expressed in
multiple cancer types and its status is required to qualify
patients for certain immuno-oncology therapeutics. AR expression is
prevalent in patients with advanced prostate cancer.
"We are delighted to be working with Dr. Gupta, who is
internationally recognized as the principal investigator for
several high-impact clinical trials with novel targeted
therapeutics and immunotherapy agents for patients with bladder and
prostate cancers," said Veena Singh,
MD, Biocept's Senior Vice President and Senior Medical
Director. "Dr. Gupta has been an active speaker at national
and international forums discussing the role of novel therapeutics
for personalized medicine in prostate cancer."
Dr. Gupta added, "Tissue sample collection and cystoscopy are
the standard methods for detecting bladder and prostate cancers,
and these methods are invasive and can be expensive. Biocept's
liquid biopsy tests have shown high concordance with tissue
biopsies in detecting genetic mutations associated with multiple
cancers, and this study is aimed at providing additional clinical
support for the use of these tests specifically in bladder and
prostate cancers."
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
information for treating and monitoring patients diagnosed with
cancer. The Company's patented Target Selector™ liquid biopsy
technology platform captures and analyzes tumor-associated
molecular markers in both CTCs and in plasma (ctDNA). With
thousands of tests performed, the platform has demonstrated the
ability to identify cancer mutations and alterations to inform
physicians about a patient's disease and therapeutic
options. For additional information, please visit
www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to our ability to improve the
diagnosis and treatment of cancer, the utility of our liquid biopsy
technology platform to detect the expression of PD-L1 and AR
expression in patients diagnosed with bladder and prostate cancers,
and our ability to obtain additional clinical support for the use
of our liquid biopsy technology platform, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at www.sec.gov.
Logo - http://photos.prnewswire.com/prnh/20151013/276540LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biocept-to-collaborate-with-renowned-clinical-investigator-dr-shilpa-gupta-to-study-the-utility-of-liquid-biopsy-testing-in-bladder-and-prostate-cancers-300325395.html
SOURCE Biocept, Inc.